Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
6.681 USD | +6.05% | +5.55% | -4.56% |
04-02 | HC Wainwright Trims KALA BIO's Price Target to $21 From $22, Keeps Buy Rating | MT |
03-29 | KALA BIO, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 17.74M 24.25M |
---|---|---|---|---|---|
Net income 2024 * | -40M -54.66M | Net income 2025 * | -42M -57.4M | EV / Sales 2024 * | - |
Net Debt 2024 * | 2.46M 3.37M | Net cash position 2025 * | 39.69M 54.24M | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-0.62
x | P/E ratio 2025 * |
-0.55
x | Employees | 43 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 82.05% |
1 day | +6.05% | ||
1 week | +5.55% | ||
Current month | -16.17% | ||
1 month | -16.38% | ||
3 months | -8.35% | ||
6 months | -3.45% | ||
Current year | -4.56% |
Managers | Title | Age | Since |
---|---|---|---|
Mark Iwicki
CEO | Chief Executive Officer | 57 | 15-02-28 |
Mary Reumuth
DFI | Director of Finance/CFO | 48 | 14-01-31 |
Todd Bazemore
PSD | President | 53 | 17-11-19 |
Members of the board | Title | Age | Since |
---|---|---|---|
Andrew Koven
BRD | Director/Board Member | 66 | 17-09-27 |
Gregory Perry
BRD | Director/Board Member | 63 | 18-03-04 |
Howard Rosen
BRD | Director/Board Member | 66 | 14-01-05 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-29 | 6.681 | +6.05% | 6 644 |
24-04-26 | 6.3 | +1.94% | 5,721 |
24-04-25 | 6.18 | -3.44% | 8,260 |
24-04-24 | 6.4 | -2.53% | 1,101 |
24-04-23 | 6.566 | +3.73% | 5,284 |
Delayed Quote Nasdaq, April 29, 2024 at 02:59 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-4.56% | 17.74M | |
+25.67% | 661B | |
+26.74% | 566B | |
-6.73% | 352B | |
+18.79% | 332B | |
+3.30% | 283B | |
+13.43% | 231B | |
+4.71% | 200B | |
-9.53% | 195B | |
-4.41% | 145B |
- Stock Market
- Equities
- KALA Stock